119 Results

People

  1. Hudis
    Hudis
  2. Lewis
    Lewis
  3. Modi
    Modi
  4. Baselga
    Baselga
  5. Chandarlapaty
    Chandarlapaty
  6. Ross
    Ross
  7. Ilson
    Ilson
  8. Janjigian
    Janjigian
  9. Jhaveri
    Jhaveri
  10. Patil
    Patil

Groups

  1. Department of Medicine (74)
  2. Solid Tumor Oncology Division (71)
  3. Breast Medicine Service (42)
  4. Survivorship Research (31)
  5. GSK Faculty (29)
  6. Department of Pathology and Laboratory Medicine (25)
  7. Radiology, Department of (21)
  8. Sloan Kettering Institute Postdocs (21)
  9. Gastrointestinal Oncology Service (19)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (18)
  1. "her2"
Formats
  1. Journal Article (103)
  2. Review (13)
  3. Meeting Abstract (2)
  4. Conference Paper (1)
Groups
  1. Department of Medicine (74)
  2. Solid Tumor Oncology Division (71)
  3. Breast Medicine Service (42)
  4. Survivorship Research (31)
  5. GSK Faculty (29)
  6. Department of Pathology and Laboratory Medicine (25)

More Groups

People
  1. Clifford Hudis (18)
  2. Jose Baselga (11)
  3. Jason Lewis (10)
  4. Shanu Modi (10)
  5. Sarat Chandarlapaty (9)
  6. Dara Ross (8)

More People

Years
  1. 2025 (1)
  2. 2024 (15)
  3. 2023 (5)
  4. 2022 (5)
  5. 2021 (2)
  6. 2020 (7)

More Years

Publications
  1. Breast Cancer Research and Treatment (9)
  2. Annals of Oncology (8)
  3. Journal of Nuclear Medicine (5)
  4. Clinical Breast Cancer (4)
  5. Journal of Thoracic Oncology (4)
  6. Oncogene (4)

More Publications

Publishers
  1. Elsevier Inc. (23)
  2. Springer (18)
  3. Oxford University Press (9)
  4. Nature Publishing Group (7)
  5. Informa Healthcare (6)
  6. Lippincott Williams & Wilkins (6)

More Publishers

Results (119)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
    Journal Article

    Hudis, C.; Swanton, C.; Janjigian, Y. Y.; Lee, R.; Sutherland, S.; Lehman, R.; Chandarlapaty, S.; Hamilton, N.; Gajria, D.; Knowles, J.; more...
    Breast Cancer Research (2013)

    Fulltext@MSK | Save
  • Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
    Journal Article

    Miles, D.; Baselga, J.; Amadori, D.; Sunpaweravong, P.; Semiglazov, V.; Knott, A.; Clark, E.; Ross, G.; Swain, S. M.
    Breast Cancer Research and Treatment (2013)

    Fulltext@MSK | Save
  • A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Journal Article

    Tolaney Dr, S. M.; Najita, J.; Sperinde, J.; Huang, W.; Chen, W. Y.; Savoie, J.; Fornier, M.; Winer, E. P.; Bunnell, C.; Krop, I. E.
    Annals of Oncology (2013)

    Fulltext@MSK | Save
  • Identifying the challenges of biomarkers that predict response to HER2-directed therapies
    Journal Article

    Iyengar, N. M.; Morris, P. G.
    Expert Opinion on Pharmacotherapy (2013)

    Fulltext@MSK | Save
  • Emerging tyrosine kinase inhibitors for esophageal cancer
    Journal Article

    Ku, G. Y.; Ilson, D. H.
    Expert Opinion on Emerging Drugs (2013)

    Fulltext@MSK | Save
  • Monitoring afatinib treatment in HER2-positive gastric cancer with (18)F-FDG and (89)Zr-trastuzumab PET
    Journal Article

    Janjigian, Y. Y.; Viola-Villegas, N.; Holland, J. P.; Divilov, V.; Carlin, S. D.; Gomes DaGama, E. M.; Chiosis, G.; Carbonetti, G.; de Stanchina, E.; Lewis, J. S.
    Journal of Nuclear Medicine (2013)

    Fulltext@MSK | Save
  • Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study
    Journal Article

    Swain, S. M.; Ewer, M. S.; Cortes, J.; Amadori, D.; Miles, D.; Knott, A.; Clark, E.; Benyunes, M. C.; Ross, G.; Baselga, J.
    The Oncologist (2013)

    Fulltext@MSK | Save
  • Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
    Journal Article

    Kaklamani, V. G.; Siziopikou, K.; Scholtens, D.; Lacouture, M.; Gordon, J.; Uthe, R.; Meservey, C.; Hansen, N.; Khan, S. A.; Jeruss, J. S.; more...
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save
  • The role of targeted therapy and biomarkers in breast cancer treatment
    Journal Article

    Stopeck, A. T.; Brown-Glaberman, U.; Wong, H. Y.; Park, B. H.; Barnato, S. E.; Gradishar, W. J.; Hudis, C. A.; Rugo, H. S.
    Clinical and Experimental Metastasis (2012)

    Fulltext@MSK | Save
  • Risk of rash with the anti-HER2 dimerization antibody pertuzumab: A meta-analysis
    Journal Article

    Drucker, A. M.; Wu, S.; Dang, C. T.; Lacouture, M. E.
    Breast Cancer Research and Treatment (2012)

    Fulltext@MSK | Save